CN106414456B - 用于预防和治疗神经退行性疾病和疼痛的化合物 - Google Patents
用于预防和治疗神经退行性疾病和疼痛的化合物 Download PDFInfo
- Publication number
- CN106414456B CN106414456B CN201480058727.3A CN201480058727A CN106414456B CN 106414456 B CN106414456 B CN 106414456B CN 201480058727 A CN201480058727 A CN 201480058727A CN 106414456 B CN106414456 B CN 106414456B
- Authority
- CN
- China
- Prior art keywords
- base
- adenosine
- methyl
- pain
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894699P | 2013-10-23 | 2013-10-23 | |
| US61/894,699 | 2013-10-23 | ||
| PCT/US2014/061734 WO2015061426A1 (en) | 2013-10-23 | 2014-10-22 | Compounds for use in prevention and treatment of neurodegenerative diseases and pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106414456A CN106414456A (zh) | 2017-02-15 |
| CN106414456B true CN106414456B (zh) | 2018-12-14 |
Family
ID=52993493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480058727.3A Active CN106414456B (zh) | 2013-10-23 | 2014-10-22 | 用于预防和治疗神经退行性疾病和疼痛的化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10301348B2 (https=) |
| EP (1) | EP3060566B1 (https=) |
| JP (1) | JP6534997B2 (https=) |
| KR (1) | KR102313314B1 (https=) |
| CN (1) | CN106414456B (https=) |
| AU (1) | AU2014340114B2 (https=) |
| BR (1) | BR112016008901B1 (https=) |
| CA (1) | CA2927699C (https=) |
| IL (1) | IL245103B (https=) |
| MX (1) | MX367707B (https=) |
| RU (1) | RU2695358C2 (https=) |
| SG (1) | SG11201603063WA (https=) |
| WO (1) | WO2015061426A1 (https=) |
| ZA (1) | ZA201603118B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201707513QA (en) * | 2015-05-29 | 2017-10-30 | Univ Leland Stanford Junior | Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes |
| US11753432B2 (en) | 2017-01-27 | 2023-09-12 | Academia Sinica | Compound with analgesic effect for use in prevention and treatment of pain |
| CA3250090A1 (en) * | 2022-02-10 | 2023-08-17 | Academia Sinica | METHOD FOR TREATMENT OF A SPINAL CORD INJURY AND CORRESPONDING COMPOSITION |
| TWI910441B (zh) * | 2022-07-07 | 2026-01-01 | 中央研究院 | 治療思覺失調症之方法及用於其中之組成物 |
| JP2026503973A (ja) * | 2022-12-29 | 2026-02-03 | 中央研究院 | 睡眠障害を処置する方法及びそれに使用するための組成物 |
| EP4680230A1 (en) * | 2023-03-17 | 2026-01-21 | Academia Sinica | Method of treating tuberous sclerosis complex or epilepsy and composition for use therein |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003148A2 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Heteroaromatic derivatives of adenoside |
| US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
| CN1148811A (zh) * | 1994-04-19 | 1997-04-30 | 罗纳·布朗克罗尔药制品有限公司 | 具有抗高血压、保护心脏、抗局部缺血和抗脂解性质的化合物 |
| WO2012064340A1 (en) * | 2009-11-13 | 2012-05-18 | Academia Sinica | Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases |
| WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU654507B2 (en) * | 1990-09-25 | 1994-11-10 | Rhone-Poulenc Rorer International (Holdings) Inc. | Compounds having antihypertensive and anti-ischemic properties |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| CN102812033B (zh) | 2009-12-10 | 2015-11-25 | 中国医学科学院药物研究所 | N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途 |
| CA2897675C (en) | 2012-02-09 | 2017-07-18 | Brandbumps, Llc | Decorative detectable warning panel having improved grip |
-
2014
- 2014-10-22 US US15/031,711 patent/US10301348B2/en active Active
- 2014-10-22 EP EP14855465.2A patent/EP3060566B1/en active Active
- 2014-10-22 JP JP2016525563A patent/JP6534997B2/ja active Active
- 2014-10-22 AU AU2014340114A patent/AU2014340114B2/en active Active
- 2014-10-22 BR BR112016008901-4A patent/BR112016008901B1/pt active IP Right Grant
- 2014-10-22 WO PCT/US2014/061734 patent/WO2015061426A1/en not_active Ceased
- 2014-10-22 MX MX2016005174A patent/MX367707B/es active IP Right Grant
- 2014-10-22 CA CA2927699A patent/CA2927699C/en active Active
- 2014-10-22 CN CN201480058727.3A patent/CN106414456B/zh active Active
- 2014-10-22 KR KR1020167013624A patent/KR102313314B1/ko active Active
- 2014-10-22 SG SG11201603063WA patent/SG11201603063WA/en unknown
- 2014-10-22 RU RU2016118282A patent/RU2695358C2/ru active
-
2016
- 2016-04-13 IL IL245103A patent/IL245103B/en active IP Right Grant
- 2016-05-10 ZA ZA2016/03118A patent/ZA201603118B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003148A2 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Heteroaromatic derivatives of adenoside |
| US5034381A (en) * | 1988-01-07 | 1991-07-23 | Ciba-Geigy Corporation | 2-(substituted amino) adenosines as antihypertensives |
| CN1148811A (zh) * | 1994-04-19 | 1997-04-30 | 罗纳·布朗克罗尔药制品有限公司 | 具有抗高血压、保护心脏、抗局部缺血和抗脂解性质的化合物 |
| WO2012064340A1 (en) * | 2009-11-13 | 2012-05-18 | Academia Sinica | Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases |
| WO2013120078A1 (en) * | 2012-02-11 | 2013-08-15 | Academia Sinica | Methods and compositions for treating pain |
Non-Patent Citations (3)
| Title |
|---|
| "Caffeine and Adenosine A2A Receptor Inactivation Decrease Striatal Neuropathology in a Lentiviral-Based Model of Machado–Joseph Disease";Nelio Goncalves et al.;《ANNALS of Neurology》;20130426;第73卷(第5期);第655-666页 * |
| "D- and L-2",3"-Didehydro-2",3"-dideoxy-3"-fluoro-carbocyclic Nucleosides: Synthesis, Anti-HIV Activity and Mechanism of Resistance";Jianing Wang et al.;《Journal of Medicinal Chemistry》;20070321;第50卷(第8期);第1828-1839页 * |
| "Synthesis of 6-15N and 1-15N labeled adenosine monophosphates";Simon R. Scarfati et al.;《Tetrahedron》;19881231;第44卷(第20期);第6368页Scheme 1，第6371页化合物6-8的制备 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016008901A2 (pt) | 2020-05-12 |
| AU2014340114B2 (en) | 2018-10-18 |
| EP3060566A1 (en) | 2016-08-31 |
| US10301348B2 (en) | 2019-05-28 |
| NZ719740A (en) | 2021-02-26 |
| MX2016005174A (es) | 2016-08-11 |
| RU2016118282A (ru) | 2017-11-28 |
| JP6534997B2 (ja) | 2019-06-26 |
| CA2927699C (en) | 2022-07-05 |
| EP3060566B1 (en) | 2018-09-05 |
| KR102313314B1 (ko) | 2021-10-19 |
| SG11201603063WA (en) | 2016-05-30 |
| RU2016118282A3 (https=) | 2018-06-18 |
| RU2695358C2 (ru) | 2019-07-23 |
| KR20160086852A (ko) | 2016-07-20 |
| EP3060566A4 (en) | 2017-06-14 |
| IL245103A0 (en) | 2016-06-30 |
| AU2014340114A1 (en) | 2016-05-26 |
| BR112016008901B1 (pt) | 2022-08-23 |
| US20160264613A1 (en) | 2016-09-15 |
| JP2016535019A (ja) | 2016-11-10 |
| ZA201603118B (en) | 2019-04-24 |
| CN106414456A (zh) | 2017-02-15 |
| WO2015061426A1 (en) | 2015-04-30 |
| IL245103B (en) | 2019-02-28 |
| CA2927699A1 (en) | 2015-04-30 |
| MX367707B (es) | 2019-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106414456B (zh) | 用于预防和治疗神经退行性疾病和疼痛的化合物 | |
| AU2019290197B2 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| CN102271681B (zh) | Cxcr7调节剂 | |
| CN116332873A (zh) | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 | |
| BR112020012997A2 (pt) | degradadores de irak e usos dos mesmos | |
| WO2015183794A1 (en) | Tgr5 agonist complexes for treating diabetes and cancer | |
| JP2020519625A (ja) | 疾患の予防および治療用の化合物およびその使用 | |
| JP2012511583A (ja) | 細胞透過性ペプチドを用いたキナーゼ阻害剤 | |
| CN102428093A (zh) | 基于吉西他滨结构的前药及其合成方法及应用 | |
| KR20180094938A (ko) | 오피오이드 수용체 리간드와 시토크롬 p450 억제제의 결합 | |
| US20230019236A1 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
| Li et al. | Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression | |
| JP2024506904A (ja) | 治療剤としてのｃＧＡＳ活性の阻害剤 | |
| TW202304888A (zh) | 醚連接之抗病毒化合物 | |
| CN116710429A (zh) | IRE1α抑制剂及其用途 | |
| TWI650328B (zh) | 用於預防及治療神經退化疾病及疼痛之化合物 | |
| Zhang et al. | SP1-mediated SYN1 promotes hemin-induced damage in PC12 cells in vitro and exacerbates blood-barrier disruption and brain injury after intracerebral hemorrhage in vivo | |
| TWI668007B (zh) | 用於預防及治療神經退化疾病及疼痛之化合物 | |
| WO2024080509A1 (ko) | Igf-1 수용체 결합 압타머 및 이의 용도 | |
| WO2024222662A1 (zh) | 一种抗体偶联药物的用途 | |
| WO2025074997A1 (ja) | ウイルス増殖阻害活性を有する縮合複素環誘導体およびそれらを含有する医薬組成物 | |
| WO2026075971A1 (en) | Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors | |
| HK40104905A (zh) | 用於调节强直性肌营养不良1型的方法和化合物 | |
| CN117813293A (zh) | 可用于治疗癌症的脲衍生物 | |
| Fedorovich et al. | P. 1. c. 005 Influence of inhibitory neurotransmitters on glutamate release and chloride content in rat brain synaptosomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |